26 completed, 10 active not recruiting, 7 terminated, 5 recruiting. 52 Phase 2, 7 Phase 1, 3 Phase 3.
Follow Thyroid Cancer, Papillary: new trials by email Literature Review of Thyroid Cancer, Papillary trials Research Report on Thyroid Cancer, Papillary
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Sacituzumab Tirumotecan in Recurrent/Metastatic Adenoid Cystic Carcinoma and Papillary Thyroid Carcinoma (STRAP) Sacituzumab Tirumotecan - Recurrent Adenoid Cystic Carcinoma, Adenoid Cystic Carcinoma Metastatic | Phase 2 | Not yet recruiting | National Cancer Centre, Singapore | 68 | 2026-11-01 | 2026-07-15 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| XL092 for the Treatment of Locally Advanced or Metastatic Radioiodine Refractory Differentiated Thyroid Cancer Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging - Locally Advanced Differentiated Thyroid Gland Carcinoma, Locally Advanced Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Recruiting | Jochen Lorch | 33 | 2025-06-06 | 2026-06-26 |
| Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E Mutation Biospecimen Collection, Cobimetinib, Computed Tomography - Thyroid Gland Follicular Carcinoma, Thyroid Gland Oncocytic Carcinoma | Phase 2 | Recruiting | City of Hope Medical Center | 21 | 2024-07-15 | 2026-02-02 |
| Restor. I-131 Upt. + Selpercatinib in RET F-P RAI-R TC Selpercatinib, Sodium Iodine I-131, rhTSH - Thyroid Cancer, Thyroid Carcinoma | Phase 2 | Recruiting | Massachusetts General Hospital | 30 | 2023-03-01 | 2024-12-12 |
| DETERMINE Trial Treatment Arm 05: Vemurafenib in Combination With Cobimetinib in Adult Patients With BRAF Positive Cancers. Vemurafenib, Cobimetinib - Haematological Malignancy, Melanoma | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-03-01 | 2025-11-24 |
| Oral AMXT 1501 Dicaprate in Combination With IV DFMO AMXT1501, DFMO - Cancer, Solid Tumor | Phase 1 / Phase 2 | Terminated | Aminex Therapeutics, Inc. | 15 | 2022-11-29 | 2024-12-24 |
| Tovorafenib (DAY101) Monotherapy for Patients With Melanoma and Other Solid Tumors Tovorafenib - Melanoma, Solid Tumor | Phase 2 | Terminated | Day One Biopharmaceuticals, Inc. | 23 | 2021-07-15 | 2025-10-02 |
| A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors Alectinib - Neoplasms, Colorectal Neoplasms | Phase 2 | Terminated | Hoffmann-La Roche | 1 | 2021-05-24 | 2023-08-07 |
| A Study of CM24 in Combination with Nivolumab in Adults with Advanced Solid Tumors CM-24 and Nivolumab - Dose Escalation, CM-24, Nivolumab, Nab paclitaxel and Gemcitabine - Expansion, CM-24, Nivolumab, and Nal-IRI/5-FU/LV - Expansion - Solid Tumor, Non Small Cell Lung Cancer | Phase 1 / Phase 2 | Completed | Famewave Ltd. | 79 | 2021-03-19 | 2024-12-27 |
| Selpercatinib Before Surgery for the Treatment of RET-Altered Thyroid Cancer Quality-of-Life Assessment, Questionnaire Administration, Selpercatinib - Malignant Thyroid Gland Neoplasm, Poorly Differentiated Thyroid Gland Carcinoma | Phase 2 | Active not recruiting | M.D. Anderson Cancer Center | 30 | 2021-02-26 | 2026-05-20 |
| PDR001 Combination Therapy for Radioiodine-Refractory Thyroid Cancer Trametinib, Dabrafenib, PDR001 - Thyroid Cancer, Thyroid Cancer, Follicular | Phase 2 | Active not recruiting | Memorial Sloan Kettering Cancer Center | 19 | 2020-09-02 | 2026-09-17 |
| Testing the Combination of Cabozantinib, Nivolumab, and Ipilimumab (CaboNivoIpi) for Advanced Differentiated Thyroid Cancer Biospecimen Collection, Cabozantinib S-malate, Computed Tomography - Differentiated Thyroid Gland Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Active not recruiting | National Cancer Institute (NCI) | 11 | 2020-02-10 | 2026-07-31 |
| A Study of Oral LOXO-292 (Selpercatinib) in Pediatric Participants With Advanced Solid or Primary Central Nervous System (CNS) Tumors Selpercatinib - Medullary Thyroid Cancer, Infantile Myofibromatosis | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 36 | 2019-06-13 | 2026-01-06 |
| Durvalumab Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma -The DUTHY Trial Durvalumab, Tremelimumab - Metastatic Thyroid Papillary Carcinoma, Metastatic Thyroid Follicular Carcinoma | Phase 2 | Terminated | Grupo Espanol de Tumores Neuroendocrinos | 79 | 2019-04-02 | 2026-03-11 |
| Lenvatinib and Iodine Therapy in Treating Patients With Radioactive Iodine-Sensitive Differentiated Thyroid Cancer Lenvatinib - Differentiated Thyroid Gland Carcinoma, Thyroid Gland Follicular Carcinoma | Phase 2 | Terminated | Emory University | 4 | 2019-01-16 | 2022-11-10 |
| Adaptive Tyrosine Kinase Inhibitor (TKI) Therapy In Patients With Thyroid Cancer Lenvatinib, Sorafenib, Cabozantinib - Thyroid Cancer, Thyroid Cancer, Medullary | Phase 2 | Terminated | H. Lee Moffitt Cancer Center and Research Institute | 6 | 2018-08-06 | 2021-07-14 |
| Lenvatinib and Pembrolizumab in Differentiated Thyroid Cancers (DTC) Laboratory Biomarker Analysis, Lenvatinib, Lenvatinib Mesylate - Columnar Cell Variant Thyroid Gland Papillary Carcinoma, Follicular Variant Thyroid Gland Papillary Carcinoma | Phase 2 | Completed | Academic and Community Cancer Research United | 57 | 2018-02-07 | 2025-08-29 |
| A Study of Selpercatinib (LOXO-292) in Participants With Advanced Solid Tumors, RET Fusion-Positive Solid Tumors, and Medullary Thyroid Cancer (LIBRETTO-001) LOXO-292 - Non-Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Active not recruiting | Eli Lilly and Company | 857 | 2017-05-02 | 2026-04-16 |
| Phase 1/2 Study of the Highly-selective RET Inhibitor, Pralsetinib (BLU-667), in Participants With Thyroid Cancer, Non-Small Cell Lung Cancer, and Other Advanced Solid Tumors pralsetinib (BLU-667) - RET-altered Non Small Cell Lung Cancer, Medullary Thyroid Cancer | Phase 1 / Phase 2 | Completed | Hoffmann-La Roche | 590 | 2017-03-17 | 2025-05-31 |
Showing 20 of 52. Sign in to see all of them.
Thyroid Neoplasms (37) · Adenocarcinoma, Follicular (35) · Carcinoma, Medullary (16) · Head and Neck Neoplasms (14) · Carcinoma, Non-Small-Cell Lung (11) · Thyroid Carcinoma, Anaplastic (9) · Colorectal Neoplasms (8) · Neoplasms (8) · Melanoma (7) · Breast Neoplasms (6) · Neoplasms by Site (6) · Ovarian Neoplasms (6) · Pancreatic Neoplasms (6) · Thyroid cancer, Hurthle cell (6)
Adenocarcinoma (51) · Adenocarcinoma, Papillary (51) · Carcinoma (51) · Neoplasms, Glandular and Epithelial (51) · Endocrine Gland Neoplasms (49) · Endocrine System Diseases (49) · Neoplasms by Histologic Type (49) · Thyroid Diseases (48) · Neoplasms by Site (46) · Neoplasms (44) · Head and Neck Neoplasms (38) · Neoplasms, Germ Cell and Embryonal (24) · Neoplasms, Nerve Tissue (24) · Neuroectodermal Tumors (24) · Neuroendocrine Tumors (20)
Magnetic Resonance Spectroscopy (8) · Iodine-131 (5) · selpercatinib (4) · trametinib (4) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (3) · Fluorodeoxyglucose F18 (3) · Sorafenib (3) · Specimen Handling (3) · Sunitinib (3) · Thyrotropin Alfa (3) · Vemurafenib (3) · dabrafenib (3) · lenvatinib (3) · AZD 6244 (2) · Everolimus (2)
National Cancer Institute (NCI) (15) · Hoffmann-La Roche (4) · Academic and Community Cancer Research United (2) · Cancer Research UK (2) · Eli Lilly and Company (2) · M.D. Anderson Cancer Center (2) · Massachusetts General Hospital (2) · Amgen (1) · Aminex Therapeutics, Inc. (1) · Bhavana Konda (1) · City of Hope Medical Center (1) · Day One Biopharmaceuticals, Inc. (1) · Emory University (1) · Famewave Ltd. (1) · Grupo Espanol de Tumores Neuroendocrinos (1)
United States (42) · Canada (8) · Spain (8) · United Kingdom (8) · South Korea (7) · Australia (6) · France (6) · Germany (5) · Italy (5) · Hong Kong (4) · Japan (4) · Singapore (4) · Belgium (3) · China (3) · Netherlands (3)
Manisha Shah (3) · Alan L Ho (2) · David Pfister (2) · Steven Sherman (2) · AeRang Kim, MD (1) · Alan L Ho, MD, PhD (1) · Barry L. Gause, MD (1) · Bhavana Konda (1) · Bhavana Konda, MD (1) · Bryan R Haugen (1) · Byung Chul Cho (1) · Chih-Yi Liao (1) · Christine H. Chung, M.D. (1)
PMID 31838007, PMID 37934000, PMID 40086048, PMID 16522694, PMID 17985985, PMID 18596272, PMID 18854394, PMID 20739388, PMID 24050953, PMID 26671977, PMID 27169792, PMID 28817373, PMID 29118225, PMID 29710208, PMID 31085763, PMID 31838015, PMID 32846060, PMID 32846061, PMID 33646820, PMID 33720068, PMID 33759836, PMID 34088726, PMID 34118197, PMID 34118198, PMID 34427452, PMID 34924145, PMID 35395680, PMID 35658604, PMID 35715405, PMID 35930972, PMID 35962206, PMID 36108661, PMID 36122315, PMID 36657661, PMID 36924196, PMID 37219859, PMID 37265412, PMID 37282666, PMID 37916501, PMID 38009200, PMID 38661071, PMID 38848521, PMID 39085487, PMID 39094065, PMID 39133806, PMID 39471424, PMID 39549678, PMID 39983053, PMID 40341199, PMID 40543520
N01CM62207 (4), N01CM62201 (3), N01CM62206 (3), P30CA015083 (3), 2023 (2), N01CM00071 (2), N01CM00099 (2), N01CM62202 (2), N01CM62203 (2), P30CA008748 (2), P30CA014599 (2), P30CA016058 (2), 2015 (1), 2016 (1), 2017 (1)